Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01167725 · ClinicalTrials.gov registry record · Phase 3
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
NCT01167725 is a Phase 3 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 340 participants.
The verdict
NCT01167725, a Phase 3 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating mitomycin C to several degrees above normal body temperature and infusing it into the area around the tumor may kill more tumor cells. Giving mitomycin C after surgery may kill any remaining tumor cells. It is not yet known whether standard therapy is more effective with or without surgery followed by mitomycin C. PURPOSE: This randomized phase III trial is studying standard therapy with or without surgery and mitomycin C in treating patients with advanced limited peritoneal dissemination of colon cancer
Interventions
- DRUG FOLFOX regimen
- BIOLOGICAL cetuximab
- DRUG capecitabine
- BIOLOGICAL bevacizumab
- DRUG FOLFIRI regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01167725
The ClinicalTrials.gov registry entry for NCT01167725 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FOLFOX regimen is the first listed.
NCT01167725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01167725 about?
NCT01167725 is a clinical study titled "Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating mitomycin C to several degrees above normal body temperature and infusing it into the area around the tumor may kill more tumor cells...
What is the current status of trial NCT01167725?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2010-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01167725?
The interventions under investigation include: FOLFOX regimen (DRUG), cetuximab (BIOLOGICAL), capecitabine (DRUG), bevacizumab (BIOLOGICAL), FOLFIRI regimen (DRUG).
Who is sponsoring clinical trial NCT01167725?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.